Chemo-ADT Combo Ups Survival in Patients with Metastatic PCa

Starting docetaxel with ADT prolonged median overall survival by more than 13 months.
Starting docetaxel with ADT prolonged median overall survival by more than 13 months.

Starting chemotherapy along with androgen deprivation therapy (ADT) in patients newly diagnosed with metastatic prostate cancer (mPCa) improved median overall survival by more than 13 months, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.

In a press conference, investigator Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute in Boston, observed, “This is one of the biggest improvements in survival we have seen in a trial involving patients with an adult metastatic solid tumor.”

The study included 790 patients randomized to receive ADT alone (393 patients) or ADT plus docetaxel (397 patients). Subjects had a median age of 63 years. A planned interim analysis showed that the median overall survival (OS) was 44 months in the ADT-only arm compared with 57.6 months in the ADT plus docetaxel arm, a difference that translated into a significant 39% decreased risk of death.

Among men with high-volume disease, the median OS in the ADT-only and combination arms was 32.2 months and 49.2 months, respectively, a 17-month difference that translated into a significant 40% decreased risk of death. In patients with low-volume disease, median OS had not been reached at the time of the analysis, according to investigators.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters